Anika Therapeutics, Inc. reported a significant improvement in its financial performance for the second quarter of 2026, with revenues reaching $32.6 million, a 16% increase from $28.2 million in the same period of 2025. For the first half of 2026, total revenue was $62.2 million, up 14% from $54.4 million year-over-year. The company achieved a gross profit of $21.2 million for the quarter, representing a 48% increase compared to $14.4 million in Q2 2025, and a gross margin of 65%, up from 51% in the prior year. This growth was primarily driven by increased sales from its Original Equipment Manufacturer (OEM) channel, particularly with Johnson & Johnson MedTech, and higher international sales of its OA pain management products.

In terms of profitability, Anika reported a net income of $3.3 million for the second quarter of 2026, a substantial turnaround from a net loss of $4.0 million in the same quarter of 2025. The company also narrowed its losses for the first half of 2026 to $1.7 million, compared to a loss of $8.8 million in the prior year. The improved financial results were attributed to higher sales volumes, increased manufacturing efficiency, and a reduction in operating expenses, which totaled $18.3 million for the quarter, slightly down from $18.5 million in Q2 2025.

Strategically, Anika has focused on its core business areas of osteoarthritis pain management and regenerative solutions. The company has made significant strides in advancing its product pipeline, including the Integrity Implant System and Cingal, a novel OA pain management product. Cingal is currently sold in over 35 countries and is undergoing regulatory review for U.S. approval. The company has also engaged in workforce restructuring to streamline operations, resulting in a reduction of general and administrative expenses.

Operationally, Anika's customer base remains strong, with a notable reliance on J&J MedTech, which accounted for 53% of total revenue in Q2 2026. The company has also seen growth in its international markets, with European sales increasing to 21% of total revenue, up from 17% in the previous year. As of June 30, 2026, Anika had cash and cash equivalents of $38.4 million, down from $57.5 million at the end of 2025, reflecting increased investments in inventory and operational activities.

Looking ahead, Anika Therapeutics is optimistic about its growth trajectory, emphasizing its commitment to advancing its product offerings and expanding its market presence. The company plans to leverage its proprietary hyaluronic acid technology to develop new solutions in OA pain management and regenerative medicine, while also exploring potential partnerships and acquisitions to enhance its capabilities. The outlook remains cautiously optimistic, with management highlighting the importance of regulatory approvals and market conditions in shaping future performance.

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc. develops and manufactures hyaluronic acid (HA)-based medical products focused on osteoarthritis (OA) pain management and regenerative orthopedic solutions. Its key offerings include viscosupplements like Monovisc and Orthovisc, and regenerative products such as the Integrity Implant System and Hyalofast scaffold. Serving global markets through direct sales and distributor networks, Anika targets clinicians and surgeons with innovative, clinically supported therapies designed to improve patient outcomes in early intervention orthopedics.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov